Literature DB >> 16858611

Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Cassio Girardi1, Marc Tonnellier, Ivan Goldstein, Alfonso Sartorius, Frederic Wallet, Jean-Jacques Rouby.   

Abstract

OBJECTIVE: Lung tissue deposition of intravenous ceftazidime administered either continuously or intermittently was compared in ventilated piglets with experimental bronchopneumonia.
DESIGN: Prospective experimental study ANIMALS: Eighteen anesthetized and ventilated piglets
INTERVENTIONS: Bronchopneumonia was produced by the intrabronchial inoculation of Pseudomonas aeruginosa characterized by an impaired sensitivity to ceftazidime (MIC 16 mg/l). Ceftazidime was administered either through a continuous infusion of 90 mg/kg per 24 h after a bolus of 30 mg/kg or by an intermittent infusion of 30 mg/kg per 8 h. MEASUREMENTS AND
RESULTS: Piglets were killed 24 h after the initiation of continuous ceftazidime (n = 6), and 1 h (peak, n = 6) and 8 h (trough, n = 6) after the third dose following intermittent administration. Lung tissue concentrations of ceftazidime, measured by HPLC, and lung bacterial burden were assessed on multiple postmortem lung specimens. During continuous administration ceftazidime lung tissue concentrations were 9.7 +/- 3.8 microg/g. Following intermittent administration peak and trough lung tissue concentrations were, respectively, 7.1 +/- 2.4 microg/g and 0.6 +/- 1 microg/g. Lung bacterial burden was different after continuous and intermittent administration (median 7.10(3) vs. 4.10(2) cfu/g).
CONCLUSIONS: Continuous infusion of ceftazidime maintained higher tissue concentrations than intermittent administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16858611     DOI: 10.1007/s00134-006-0272-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  31 in total

1.  Mechanical ventilation-induced air-space enlargement during experimental pneumonia in piglets.

Authors:  I Goldstein; M T Bughalo; C H Marquette; G Lenaour; Q Lu; J J Rouby
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

Review 2.  The standardization of criteria for processing and interpreting laboratory specimens in patients with suspected ventilator-associated pneumonia.

Authors:  V S Baselski; M el-Torky; J J Coalson; J P Griffin
Journal:  Chest       Date:  1992-11       Impact factor: 9.410

3.  In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.

Authors:  M A Robaux; L Dube; J Caillon; D Bugnon; M F Kergueris; D Navas; P Le Conte; D Baron; G Potel
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

4.  Nosocomial infection in the critically ill: the lung as a target organ.

Authors:  J J Rouby
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

5.  Pulmonary penetration of ceftazidime.

Authors:  M Cazzola; M Gabriella Matera; M Polverino; G Santangelo; I De Franchis; F Rossi
Journal:  J Chemother       Date:  1995-02       Impact factor: 1.714

Review 6.  Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

Authors:  D R Andes; W A Craig
Journal:  Infect Dis Clin North Am       Date:  1999-09       Impact factor: 5.982

7.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

9.  Characterization of an animal model of ventilator-acquired pneumonia.

Authors:  C H Marquette; D Wermert; F Wallet; M C Copin; A B Tonnel
Journal:  Chest       Date:  1999-01       Impact factor: 9.410

10.  Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.

Authors:  J J Rouby; E Martin De Lassale; P Poete; M H Nicolas; L Bodin; V Jarlier; Y Le Charpentier; J Grosset; P Viars
Journal:  Am Rev Respir Dis       Date:  1992-10
View more
  5 in total

Review 1.  Year in review in Intensive Care Medicine, 2006. I. Experimental studies. Clinical studies: brain injury, renal failure and endocrinology.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard
Journal:  Intensive Care Med       Date:  2006-12-19       Impact factor: 17.440

2.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.

Authors:  Bernard Georges; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.

Authors:  Joël Cousson; Thierry Floch; Thomas Guillard; Véronique Vernet; Pascal Raclot; Aurore Wolak-Thierry; Damien Jolly
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Authors:  Fabio Ferrari; Qin Lu; Cassio Girardi; Olivier Petitjean; Charles-Hugo Marquette; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

5.  Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock.

Authors:  Marc O Maybauer; Dirk M Maybauer; John F Fraser; Lillian D Traber; Martin Westphal; Robert A Cox; Ruksana Huda; Yoshimitsu Y Nakano; Perenlei Enkhbaatar; Hal K Hawkins; David N Herndon; Daniel L Traber
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.